Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells
- Nat Immunol. 2017 Jan;18(1):74-85. doi: 10.1038/ni.3632.
- 1. Klinikum rechts der Isar, Department of Neurology, Technical University of Munich, Munich, Germany.
- 2. Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
- 3. Institute of Biochemistry, Kiel University, Kiel, Germany.
- 4. Institute of Neuronal Cell Biology, Technical University of Munich, Munich, Germany.
- 5. Institute of Pathology, Medical School, Ludwig-Maximilians-University, Munich, Germany.
- 6. Gene Centre, Lafuga, Ludwig-Maximilians-University, Munich, Germany.
- 7. Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
- 8. Max Planck Institute for Metabolism Research, Cologne, Germany.
- 9. Department of Cellular Biology, Physiology, and Immunology, Autonomous University of Barcelona, Barcelona, Spain.
- 10. Department of Immunology, University of Washington, Seattle, Washington, USA.
- 11. Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, Washington, USA.
- 12. Department of Hematology and Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
The cellular sources of interleukin 6 (IL-6) that are relevant for differentiation of the TH17 subset of helper T cells remain unclear. Here we used a novel strategy for the conditional deletion of distinct IL-6-producing cell types to show that dendritic cells (DCs) positive for the signaling regulator Sirpα were essential for the generation of pathogenic TH17 cells. Using their IL-6 receptor α-chain (IL-6Rα), Sirpα+ DCs trans-presented IL-6 to T cells during the process of cognate interaction. While ambient IL-6 was sufficient to suppress the induction of expression of the transcription factor Foxp3 in T cells, trans-presentation of IL-6 by DC-bound IL-6Rα (called 'IL-6 cluster signaling' here) was needed to prevent premature induction of interferon-γ (IFN-γ) expression in T cells and to generate pathogenic TH17 cells in vivo. Our findings should guide therapeutic approaches for the treatment of TH17-cell-mediated autoimmune diseases.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Transmembrane GlycoproteinResearch Areas: Inflammation/Immunology